Claims:

1. A pharmaceutical combination comprising an active ingredient (a) of a taxane compound; and an active ingredient (b) of plinabulin.

2. The combination of Claim 1, wherein the taxane compound comprises paclitaxel, docetaxel, and abraxane.

3. The combination of Claim 1, wherein the combination consists of docetaxel and plinabulin.

4. Use of the pharmaceutical combination according to Claims 1-3 for preparing drugs for treating and/or preventing cancer.

5. The use of claim 4, wherein the cancer selected from the group consisting of lung cancer, colon cancer, liver cancer, breast cancer, prostate cancer, and multiple myeloma.

6. Use of a composition, a kit or a mixture comprising an active ingredient (a) of taxane and an active ingredient (b) of plinabulin for treating and/or preventing cancer,

especially a cancer with a tumor size of > 3cm, > 5cm, or >7cm.

7. A kit, containing:

(i) a first container containing a first medicament which comprises a taxane compound as an active ingredient (a) and an optional pharmaceutically acceptable carrier; and

(ii) a second container containing a second medicament which comprises plinabulin as an active ingredient (b) and an optional pharmaceutically acceptable carrier;

(iii) an instruction recording an administration of the active ingredient (a) in combination with the active ingredient (b) for treating and/or preventing cancer.

8. A pharmaceutical composition, wherein it comprises:

an active ingredient (a) of taxane;

an active ingredient (b) of plinabulin; and

(c) a pharmaceutical acceptable carrier.

9. The use of plinabulin for preparation of a medicine used to reduce side effect of taxane.

10. A method for treating and/or preventing cancer, comprising the following steps: administrating to a mammal in need thereof an active ingredient (a) of taxane and an active ingredient (b) of plinabulin.

Claims:

1. Use of plinabulin in the preparation of a medicament for the treatment of a taxane-induced grade 3 or 4 neutropenia in a subject having a taxane-induced neutropenia.

2. The use of claim 1, wherein the medicament is for administration prior to administration of the taxane.

3. The use of claim 1, wherein the medicament is for administration after administration of the taxane.

4. The use of any one of claims 1 to 3, wherein the medicament is for inducing a neutropenia rate that is lower than that induced by taxane alone.

5. The use of any one of claims 1 to 4, wherein the taxane is docetaxel.

6. The use of claim 5, wherein the taxane-induced neutropenia is induced by administration of docetaxel at a dose of about 45 mg/m^2 to 120 mg/m^2.

7. The use of claim 6, wherein the taxane-induced neutropenia is induced by administration of docetaxel at a dose of about 50 mg/m^2 to 75 mg/m^2.

8. The use of any one of claims 1 to 4, wherein the taxane is paclitaxel.

9. The use of claim 8, wherein the taxane-induced neutropenia is induced by administration of paclitaxel at a dose of about 50 to 250 mg/m^2.

10. The use of any one of claims 1 to 4, wherein the taxane is protein-bound paclitaxel.

11. The use of any one of claims 1 to 10, wherein the medicament comprises a dose of plinabulin of about 10 to 50 mg/m^2.

12. The use of claim 11, wherein the medicament comprises a dose of plinabulin of about 20 mg/m^2 or 30 mg/m^2.

13. The use of any one of claims 1 to 12, wherein the weight ratio of taxane dosage and plinabulin dosage is about 1.5:1 to 4:1.

14. The use of claim 1 or 3, wherein the medicament is for administration about 1 to 24 hours after taxane administration.

15. The use of claim 14, wherein the medicament is for administration about 2 hours after taxane administration.

16. The use of any one of claims 1 to 15, wherein the medicament is for reducing a neutropenia rate by at least 4% for grade 3 neutropenia.

17. The use of any one of claims 1 to 16, wherein the medicament is for reducing a neutropenia rate by at least 15% for grade 4 neutropenia.